

# Eduard Shantsila

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3558780/publications.pdf>

Version: 2024-02-01

194  
papers

6,822  
citations

87888

38  
h-index

69250

77  
g-index

200  
all docs

200  
docs citations

200  
times ranked

10673  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. <i>Lancet</i> , The, 2009, 373, 155-166.	13.7	873
2	Cardiac Fibrosis in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 943-959.	2.8	427
3	Endothelial Progenitor Cells in Cardiovascular Disorders. <i>Journal of the American College of Cardiology</i> , 2007, 49, 741-752.	2.8	390
4	The Role of Monocytes in Angiogenesis and Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1-11.	2.8	347
5	Monocytes in Coronary Artery Disease and Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1541-1551.	2.8	316
6	Microvesicles in vascular homeostasis and diseases. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1296-1316.	3.4	193
7	The nuclear factor $\kappa$ B pathway in atherosclerosis: A potential therapeutic target for atherothrombotic vascular disease. <i>Thrombosis Research</i> , 2011, 128, 117-123.	1.7	178
8	The CD14 <sup>++</sup> CD16 <sup>+</sup> monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1231-1241.	3.8	164
9	The role of monocytes and inflammation in the pathophysiology of heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 1161-1171.	7.1	162
10	Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1056-1066.	3.8	147
11	Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2358-2368.	3.8	143
12	Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2009, 135, 1651-1664.	0.8	124
13	The role of monocytes in thrombotic disorders. <i>Thrombosis and Haemostasis</i> , 2009, 102, 916-924.	3.4	123
14	Role and analysis of monocyte subsets in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2016, 116, 626-637.	3.4	113
15	The role of monocytes in atherosclerotic coronary artery disease. <i>Annals of Medicine</i> , 2010, 42, 394-403.	3.8	108
16	The CD40-CD40L system in cardiovascular disease. <i>Annals of Medicine</i> , 2011, 43, 331-340.	3.8	107
17	Atrial Fibrillation and Hypertension. <i>Hypertension</i> , 2017, 70, 854-861.	2.7	100
18	Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes. <i>Atherosclerosis</i> , 2013, 227, 313-322.	0.8	87

#	ARTICLE	IF	CITATIONS
19	Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. <i>Basic Research in Cardiology</i> , 2011, 106, 911-923.	5.9	80
20	Role of Monocytes in Heart Failure and Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	72
21	<scp>CD</scp>14++<scp>CD</scp>16+ monocytes in patients with acute ischaemic heart failure. <i>European Journal of Clinical Investigation</i> , 2013, 43, 121-130.	3.4	70
22	Current Understanding of Atherogenesis. <i>American Journal of Medicine</i> , 2017, 130, 268-282.	1.5	68
23	Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. <i>Cardiovascular Research</i> , 2010, 85, 649-660.	3.8	66
24	A contemporary view on endothelial function in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 873-881.	7.1	65
25	Monocytes in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1433-1438.	2.4	57
26	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , 2015, 44, 874-878.	1.6	57
27	Increased Formation of Monocyte-Platelet Aggregates in Ischemic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 127-135.	3.9	55
28	Circulating microparticles: challenges and perspectives of flow cytometric assessment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1009-1014.	3.4	55
29	The immunological axis in heart failure: importance of the leukocyte differential. <i>Heart Failure Reviews</i> , 2013, 18, 835-845.	3.9	54
30	Myocardial Perfusion by Myocardial Contrast Echocardiography and Endothelial Dysfunction in Obstructive Sleep Apnea. <i>Hypertension</i> , 2011, 58, 417-424.	2.7	50
31	Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. <i>Atherosclerosis</i> , 2014, 234, 4-10.	0.8	49
32	Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. <i>Europace</i> , 2017, 19, 1427-1438.	1.7	48
33	Persistent Macrovascular and Microvascular Dysfunction in Patients With Malignant Hypertension. <i>Hypertension</i> , 2011, 57, 490-496.	2.7	47
34	Microparticles and Arterial Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 488-496.	2.7	42
35	Atrial fibrillation post-cardiac surgery: changing perspectives. <i>Current Medical Research and Opinion</i> , 2006, 22, 1437-1441.	1.9	41
36	Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. <i>Europace</i> , 2007, 9, iv37-iv44.	1.7	41

#	ARTICLE	IF	CITATIONS
37	Left Ventricular Fibrosis in Atrial Fibrillation. American Journal of Cardiology, 2013, 111, 996-1001.	1.6	41
38	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. British Journal of General Practice, 2015, 65, e16-e23.	1.4	37
39	Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1445-1461.	3.3	36
40	Microparticles and cardiovascular diseases. Annals of Medicine, 2019, 51, 193-223.	3.8	36
41	Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis. Annals of Medicine, 2014, 46, 530-538.	3.8	35
42	The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. European Journal of Clinical Investigation, 2012, 42, 832-839.	3.4	34
43	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2017, 92, 1203-1213.	3.0	34
44	Endothelial progenitor cells: what use for the cardiologist?. Journal of Angiogenesis Research, 2010, 2, 6.	2.9	32
45	An innovative flow cytometric approach for small-size platelet microparticles: Influence of calcium. Thrombosis and Haemostasis, 2012, 108, 373-383.	3.4	31
46	Anticoagulation versus placebo for heart failure in sinus rhythm. The Cochrane Library, 2014, , CD003336.	2.8	31
47	The endothelium and thrombotic risk in heart failure. Thrombosis and Haemostasis, 2009, 102, 185-187.	3.4	30
48	Novel oral anticoagulants. International Journal of Clinical Practice, 2009, 63, 630-641.	1.7	29
49	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. Stroke, 2017, 48, 2198-2205.	2.0	29
50	Monocyte Diversity in Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 139-142.	2.8	28
51	Aspirin resistance: What, why and when?. Thrombosis Research, 2007, 119, 551-554.	1.7	26
52	'Aspirin resistance' or treatment non-compliance: Which is to blame for cardiovascular complications?. Journal of Translational Medicine, 2008, 6, 47.	4.4	26
53	Ethnic Differences in Macrovascular and Microvascular Function in Systolic Heart Failure. Circulation: Heart Failure, 2011, 4, 754-762.	3.9	26
54	Thrombotic Complications in Heart Failure. Circulation, 2014, 130, 387-389.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Endothelial colony forming units: Are they a reliable marker of endothelial progenitor cell numbers?. <i>Annals of Medicine</i> , 2007, 39, 474-479.	3.8	25
56	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , 2015, 69, 840-845.	1.7	25
57	Epidemiology and pathogenesis of diffuse obstructive coronary artery disease: the role of arterial stiffness, shear stress, monocyte subsets and circulating microparticles. <i>Annals of Medicine</i> , 2016, 48, 444-455.	3.8	25
58	Predictors of 5-year outcomes in malignant phase hypertension. <i>Journal of Hypertension</i> , 2017, 35, 2310-2314.	0.5	25
59	Small size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin. <i>British Journal of Haematology</i> , 2014, 166, 571-580.	2.5	24
60	Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. <i>Rheumatology</i> , 2008, 48, 285-288.	1.9	22
61	Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers. <i>Prostate</i> , 2011, 71, 1047-1053.	2.3	22
62	Role of Ticagrelor in Clopidogrel Nonresponders: Resistance Is Futile?. <i>Circulation</i> , 2010, 121, 1169-1171.	1.6	21
63	<sc>TLR</sc>4 expression on monocyte subsets in myocardial infarction. <i>Journal of Internal Medicine</i> , 2013, 273, 294-305.	6.0	21
64	CXCR4 positive and angiogenic monocytes in myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2013, 109, 255-262.	3.4	21
65	Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 43-53.	3.4	21
66	Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 535-544.	2.1	21
67	Circulating endothelial cells: from bench to clinical practice. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 865-868.	3.8	20
68	Endothelial microparticles: a universal marker of vascular health?. <i>Journal of Human Hypertension</i> , 2009, 23, 359-361.	2.2	20
69	A contemporary viewpoint on "aspirin resistance". <i>Annals of Medicine</i> , 2012, 44, 773-783.	3.8	20
70	Increased expression of cell adhesion molecule receptors on monocyte subsets in ischaemic heart failure. <i>Thrombosis and Haemostasis</i> , 2013, 110, 92-100.	3.4	20
71	Spirolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016239.	3.7	20
72	New antiplatelet drugs: beyond aspirin and clopidogrel. <i>International Journal of Clinical Practice</i> , 2009, 63, 776-789.	1.7	18

#	ARTICLE	IF	CITATIONS
73	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016, 102, 1878-1882.	2.9	18
74	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017, 18, 199-203.	6.1	18
75	Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways. <i>Thrombosis and Haemostasis</i> , 2012, 108, 32-40.	3.4	17
76	Anticoagulation for stroke prevention in atrial fibrillation: is gender important?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 1893-1894.	2.2	16
77	Monocyte-derived and CD34+/KDR+ endothelial progenitor cells in heart failure. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1252-1261.	3.8	16
78	Heart Failure and Stroke. <i>Current Heart Failure Reports</i> , 2018, 15, 287-296.	3.3	16
79	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". <i>Thrombosis and Haemostasis</i> , 2009, 102, 914-915.	3.4	15
80	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <i>EBioMedicine</i> , 2016, 4, 26-39.	6.1	15
81	Malignant Hypertension: A Rare Problem or is it Underdiagnosed?. <i>Current Vascular Pharmacology</i> , 2010, 8, 775-779.	1.7	15
82	Blood leukocytes in heart failure with preserved ejection fraction: Impact on prognosis. <i>International Journal of Cardiology</i> , 2012, 155, 337-338.	1.7	14
83	The effect of statin therapy withdrawal on monocyte subsets. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1307-1313.	3.4	14
84	Evaluation of Carotid Plaque Neovascularization Using Contrast Ultrasound. <i>Angiology</i> , 2013, 64, 447-450.	1.8	14
85	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e012241.	1.9	14
86	Fondaparinux: an overview. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 577-585.	1.5	13
87	Systemic inflammation as a driver of vascular calcification: a proof of concept. <i>Journal of Internal Medicine</i> , 2009, 266, 453-456.	6.0	12
88	Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation. <i>Cardiovascular Research</i> , 2018, 114, 1313-1323.	3.8	12
89	Impact of Mon2 monocyte-platelet aggregates on human coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12911.	3.4	12
90	Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 13.	3.3	12

#	ARTICLE	IF	CITATIONS
91	Antioxidant protection; yet another function of endothelial progenitor cells?. Journal of Human Hypertension, 2007, 21, 343-346.	2.2	11
92	Stroke in atrial fibrillation and improving the identification of "high-risk" patients: the crossroads of immunity and thrombosis. Journal of Thrombosis and Haemostasis, 2015, 13, 1968-1970.	3.8	11
93	Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. The Cochrane Library, 2016, 9, CD003333.	2.8	11
94	Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. Journal of Thrombosis and Haemostasis, 2007, 5, 870-872.	3.8	10
95	Mechanisms of thrombogenesis in atrial fibrillation " Authors' reply. Lancet, The, 2009, 373, 1006-1007.	13.7	10
96	The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. Cardiovascular Therapeutics, 2011, 29, e12-e22.	2.5	10
97	Systolic heart failure in South Asians. International Journal of Clinical Practice, 2011, 65, 1274-1282.	1.7	10
98	A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: The West Birmingham Malignant Hypertension project. International Journal of Cardiology, 2013, 167, 67-72.	1.7	10
99	Free Light Chains in Patients With Acute Heart Failure Secondary to Atherosclerotic Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 1243-1248.	1.6	9
100	Mon2 predicts poor outcome in <sc>ST</sc>-elevation myocardial infarction. Journal of Internal Medicine, 2019, 285, 301-316.	6.0	9
101	Antithrombotic therapy for heart failure in sinus rhythm. Fundamental and Clinical Pharmacology, 2009, 23, 705-717.	1.9	8
102	The Risk of Thromboembolism in Heart Failure: Does It Merit Anticoagulation Therapy?. American Journal of Cardiology, 2011, 107, 558-560.	1.6	8
103	Monocytes circulate in constant reversible interaction with platelets in a [Ca <sup>2+</sup> ]-dependent manner. Platelets, 2014, 25, 197-201.	2.3	8
104	Small-size Microparticles as Indicators of Acute Decompensated State in Ischemic Heart Failure. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 951-958.	0.6	8
105	The effects of exercise stress testing, diurnal variation and temporal decline on circulating progenitor cells. Thrombosis and Haemostasis, 2010, 103, 419-424.	3.4	7
106	Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders. Current Pharmaceutical Design, 2012, 18, 840-849.	1.9	7
107	Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. Thrombosis and Haemostasis, 2013, 110, 340-348.	3.4	7
108	Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. International Journal of Cardiology, 2015, 185, 322-327.	1.7	7

#	ARTICLE	IF	CITATIONS
109	Symptom-to-door times in patients presenting with ST elevation myocardial infarction—do ethnic or gender differences exist?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 175-180.	0.5	7
110	Endothelial Progenitors and Blood Microparticles: Are They Relevant to Heart Failure With Preserved Ejection Fraction?. <i>EBioMedicine</i> , 2016, 4, 5-6.	6.1	7
111	Circulating endothelial cells in health and disease: how do we best quantify them?. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1021-1024.	3.8	6
112	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. <i>Annals of Medicine</i> , 2009, 41, 608-618.	3.8	6
113	Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice. <i>International Journal of Clinical Practice</i> , 2010, 64, 835-838.	1.7	6
114	Blockade of the renin-angiotensin system in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2010, 7, 428-430.	13.7	6
115	Arterial stiffening in hypertension: beyond blood pressure levels. <i>Journal of Human Hypertension</i> , 2010, 24, 303-305.	2.2	6
116	Ventricular-arterial coupling in obstructive sleep apnea. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 624-629.	2.3	6
117	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 386-392.	3.1	6
118	Renin-angiotensin blockade in atrial fibrillation: where are we now?. <i>Journal of Human Hypertension</i> , 2017, 31, 425-426.	2.2	6
119	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019, 83, 2434-2442.	1.6	6
120	Anticoagulation versus placebo for heart failure in sinus rhythm. <i>The Cochrane Library</i> , 2021, 2021, CD003336.	2.8	6
121	Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2007, 120, 123-124.	1.7	5
122	Statins and inflammation: Reciprocal effectors to endothelial progenitors?. <i>Thrombosis Research</i> , 2008, 123, 1-4.	1.7	5
123	Predicting thrombotic events: Creating a complex approach for a complex condition. <i>Thrombosis and Haemostasis</i> , 2008, 100, 962-964.	3.4	5
124	Endothelial function and endothelial progenitors: possible mediators of the benefits from physical exercise?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 401-403.	2.8	5
125	Circulating progenitor cells in patients with atrial fibrillation and their relation with serum markers of inflammation and angiogenesis. <i>Thrombosis and Haemostasis</i> , 2010, 104, 327-334.	3.4	5
126	Circulating monocytes and atherogenesis: From animal experiments to human studies. <i>Thrombosis and Haemostasis</i> , 2010, 104, 191-193.	3.4	5



#	ARTICLE	IF	CITATIONS
127	Atorvastatin and its collateral effects on microparticles. <i>Thrombosis and Haemostasis</i> , 2011, 106, 185-186.	3.4	5
128	Recent advances in management of atrial fibrillation in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2013, 28, 197-208.	1.8	5
129	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. <i>F1000Research</i> , 2016, 5, 2887.	1.6	5
130	The search for new anticoagulants: dabigatran etexilate. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 793-796.	0.2	4
131	Angiotensin II and Preeclampsia: New Perspectives in the Quest for Markers. <i>American Journal of Hypertension</i> , 2009, 22, 820-820.	2.0	4
132	Targeting the arterial wall, but what is the target?. <i>Journal of Human Hypertension</i> , 2009, 23, 1-3.	2.2	4
133	Coronary Atherosclerosis in Rheumatoid Arthritis: Could Endothelial Progenitor Cells Be the Missing Link?. <i>Journal of Rheumatology</i> , 2010, 37, 479-481.	2.0	4
134	Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 5-9.	2.1	4
135	Ultrasound-assisted thrombolysis with streptokinase improves thrombus resolution with minimal distal embolisation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 263-270.	2.1	4
136	Pharmacokinetic considerations for antithrombotic therapies in stroke. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1335-1347.	3.3	4
137	Use of Novel Oral Anticoagulants in Patients With Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 285.	0.9	4
138	Premature Cardiac Aging in South Asian Compared to Afro-Caribbean Subjects in a Community-Based Screening Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	4
139	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2033-2047.	1.8	4
140	Predictors of diastolic dysfunction in ethnic groups: observations from the Hypertensive Cohort of The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). <i>Journal of Human Hypertension</i> , 2018, 32, 477-486.	2.2	4
141	Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation project. <i>Thrombosis Research</i> , 2021, 200, 149-155.	1.7	4
142	Altered cardiac and vascular stiffness in pregnancy after a hypertensive pregnancy. <i>Journal of Human Hypertension</i> , 2023, 37, 189-196.	2.2	4
143	New Anticoagulants for the Prevention of Deep Venous Thrombosis. <i>Pharmacoeconomics</i> , 2009, 27, 793-795.	3.3	3
144	Vascular ventricular coupling in patients with malignant phase hypertension: the West Birmingham malignant hypertension project. <i>Hypertension Research</i> , 2012, 35, 725-728.	2.7	3

#	ARTICLE	IF	CITATIONS
145	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , 2015, 65, 117-117.	1.4	3
146	Atrial fibrillation and its complications: a focus on identifying risk factors and risk stratification. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 88-89.	3.0	3
147	Stroke prevention in atrial fibrillation. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2017, 47, 13-23.	0.6	3
148	Prognostic implication of monocytes in atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>PLoS ONE</i> , 2018, 13, e0200373.	2.5	3
149	Hypertension and sleep health: a multidimensional puzzle. <i>Journal of Hypertension</i> , 2021, 39, 600-601.	0.5	3
150	CD36 expression and lipid metabolism following an oral glucose challenge in South Asians. <i>World Journal of Diabetes</i> , 2015, 6, 983.	3.5	3
151	Laboratory investigation of platelets. , 2001, , 124-146.		2
152	Beyond glucose levels in diabetic patients with coronary artery disease: Platelet activity and non-responsiveness to antiplatelet therapy. <i>Thrombosis and Haemostasis</i> , 2008, 100, 07-08.	3.4	2
153	Angiopietins in arterial hypertension: a mechanism of adaptation or a target for treatment?. <i>Journal of Hypertension</i> , 2009, 27, 1524-1526.	0.5	2
154	Soluble Fms-Like Tyrosine Kinase-1. <i>Circulation Journal</i> , 2010, 74, 2064-2065.	1.6	2
155	Platelet reactivity in prolonged stress disordersâ€™A link with cardiovascular disease?. <i>Psychoneuroendocrinology</i> , 2011, 36, 159-160.	2.7	2
156	Stroke Prevention in Atrial Fibrillation in Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 427-435.	2.1	2
157	CD4+ T cell surface alpha enolase is lower in older adults. <i>Mechanisms of Ageing and Development</i> , 2015, 152, 56-62.	4.6	2
158	What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. <i>European Heart Journal Supplements</i> , 2016, 18, I18-I24.	0.1	2
159	Treatment of Atrial Fibrillation in Patients With Chronic Kidney Disease. <i>Chest</i> , 2016, 149, 891-892.	0.8	2
160	Blood pressure targets in atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 2860-2862.	2.2	2
161	Spirolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-42.	0.7	2
162	Cardioversion and remodelling in atrial fibrillation: Insights beyond the prothrombotic state. <i>Thrombosis Research</i> , 2008, 121, 443-445.	1.7	1

#	ARTICLE	IF	CITATIONS
163	Heparin-Induced Thrombocytopenia: Response. <i>Chest</i> , 2009, 136, 1704-1705.	0.8	1
164	Vascular Imaging as a Cardiovascular Risk Stratification Tool in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2141-2143.	2.0	1
165	AZD6140 and bleeding: towards safer antiplatelet therapy?. <i>International Journal of Clinical Practice</i> , 2009, 63, 537-539.	1.7	1
166	Variability of response to antiplatelet therapy: what should we do next?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 19-22.	1.9	1
167	Evidence guided antiplatelet treatment: Time to move from bench to bedside. <i>Thrombosis Research</i> , 2009, 124, 649-650.	1.7	1
168	Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 187-189.	0.2	1
169	Aspirinâ€”A Drug Whose Time Has Gone?. <i>American Journal of Cardiology</i> , 2010, 105, 577-578.	1.6	1
170	Percutaneous Coronary Intervention in Anticoagulated Patients and Balancing the Risk of Stroke and Bleeding. <i>Chest</i> , 2010, 138, 771-774.	0.8	1
171	Monocytes: Possible mediators of benefits and harms from physical activity?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 387-389.	3.4	1
172	Endothelial dysfunction and diurnal variation of blood pressure: night secrets of arterial hypertension?. <i>Journal of Human Hypertension</i> , 2011, 25, 653-655.	2.2	1
173	The membrane expression of P-selectin, but not monocyte-platelet aggregates, is influenced by variability in response to aspirin in patients with coronary artery disease. <i>Platelets</i> , 2014, 25, 142-143.	2.3	1
174	Ethnic differences in the diurnal variation of symptom onset time for acute ST elevation myocardial infarction â€” An observational cohort study. <i>International Journal of Cardiology</i> , 2015, 187, 414-416.	1.7	1
175	Use of nonâ€”vitamin K antagonist oral anticoagulants in patients with heart failure and atrial fibrillation: does concomitant kidney disease change our practice?. <i>European Journal of Heart Failure</i> , 2016, 18, 1172-1174.	7.1	1
176	Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study. <i>Journal of Human Hypertension</i> , 2017, 31, 206-211.	2.2	1
177	Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. <i>Thrombosis Research</i> , 2021, 197, 69-76.	1.7	1
178	Heart Failure With Sinus Rhythm: Does Anticoagulation Reduce Stroke at All?. <i>Journal of Cardiac Failure</i> , 2021, 27, 865-868.	1.7	1
179	Vitamin K Antagonists and Their Limitations. , 2013, , 33-40.		1
180	Revisiting the diagnosis of â€”resistant hypertensionâ€™: what should we do nowadaysâ€™. <i>Journal of Human Hypertension</i> , 2022, 36, 337-340.	2.2	1

#	ARTICLE	IF	CITATIONS
181	Anticoagulation for Stroke Prevention. <i>Pharmacoeconomics</i> , 2006, 24, 1035-1038.	3.3	0
182	Pharmacotherapy for atrial fibrillation: is rhythm control achievable?. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1105-1107.	1.8	0
183	102 Ethnic differences in endothelial function in chronic heart failure. <i>Heart</i> , 2011, 97, A59-A59.	2.9	0
184	Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention. <i>International Journal of Clinical Practice</i> , 2015, 69, 1334-1340.	1.7	0
185	124 South Asian Ethnicity is Independently Related to Diastolic Function in Hypertension: Abstract 124 Table 1. <i>Heart</i> , 2015, 101, A71-A72.	2.9	0
186	Simultaneous computerised activation of the primary percutaneous coronary intervention pathway reduces out-of-hours door-to-balloon time but not mortality. <i>International Journal of Cardiology</i> , 2015, 186, 226-230.	1.7	0
187	Chronic Osteomyelitis and Atrial Fibrillation: Revisiting the Link Between Inflammation Burden and Arrhythmia. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1366-1368.	1.7	0
188	Letters to the editor. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2017, 47, 205-207.	0.6	0
189	Risk Stratification in Atrial Fibrillation. , 2019, , 47-66.		0
190	Alterations in the Peripheral Circulation in Heart Failure. , 2020, , 201-213.e6.		0
191	New Oral Anticoagulants. , 2013, , 53-86.		0
192	Common Clinical Indications for Anticoagulation. , 2013, , 7-31.		0
193	Therapy for atrial fibrillation: new challenges. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 445-448.	0.2	0
194	Monocytes are increased in pregnancy after gestational hypertensive disease. <i>Scientific Reports</i> , 2022, 12, .	3.3	0